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ABSTRACT Nucleic acid amplification tests (NAATs) are reliable tools for the detec-
tion of toxigenic Clostridium difficile from unformed (liquid or soft) stool samples.
The objective of this study was to evaluate performance of the cobas Cdiff test on
the cobas 4800 system using prospectively collected stool specimens from patients
suspected of having C. difficile infection (CDI). The performance of the cobas Cdiff
test was compared to the results of combined direct and broth-enriched toxigenic
culture methods in a large, multicenter clinical trial. Additional discrepancy analysis
was performed by using the Xpert C. difficile Epi test. Sample storage was evaluated
by using contrived and fresh samples before and after storage at 20°C. Testing
was performed on samples from 683 subjects (306 males and 377 females); 113
(16.5%) of 683 subjects were positive for toxigenic C. difficile by direct toxigenic cul-
ture, and 141 of 682 subjects were positive by using the combined direct and en-
riched toxigenic culture method (reference method), for a prevalence rate of 20.7%.
The sensitivity and specificity of the cobas Cdiff test compared to the combined di-
rect and enriched culture method were 92.9% (131/141; 95% confidence interval [CI],
87.4% to 96.1%) and 98.7% (534/541; 95% CI, 97.4% to 99.4%), respectively. Discrep-
ancy analysis using results for retested samples from a second NAAT (Xpert C. diffi-
cile/Epi test; Cepheid, Sunnyvale, CA) found no false-negative and 4 false-positive
cobas Cdiff test results. There was no difference in positive and negative results in
comparisons of fresh and stored samples. These results support the use of the cobas
Cdiff test as a robust aid in the diagnosis of CDI.
KEYWORDS Clostridium difficile infection (CDI), health care-associated infection,
nucleic acid amplification test, active surveillance testing (AST), toxin B (tcdB) gene
Clostridium difficile is a Gram-positive, anaerobic, spore-forming bacillus identified asan etiological agent of antibiotic-associated diarrhea and pseudomembranous
colitis in the late 1970s (1, 2). Historically, the incidence of C. difficile infection (CDI)
ranged from 30 to 40 cases per 100,000 population in acute-care hospitals in the United
States (3). The incidence rose to more than 140 cases per 100,000 population by 2013,
with 60.7% clearly being health care associated (4). Currently, CDI is the most com-
monly diagnosed infectious cause of health care-associated diarrhea and is a significant
cause of morbidity and mortality (5). Toxigenic strains of C. difficile typically produce
two toxins, toxin A, which is an enterotoxin, and toxin B, which is a cytotoxin (6). A small
percentage of strains produce only toxin B (7). There are no known naturally occurring
toxin A-positive, toxin B-negative strains associated with clinical disease (8, 9). Diagno-
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sis of CDI may be established by the presence of toxin B or toxins A and B in stool
samples from patients with appropriate clinical symptoms, driving the need for accu-
rate testing.
Early detection of CDI with the rapid implementation of contact precautions is
considered critical for infection control to prevent transmission in the health care
setting (10). There are various diagnostic approaches for CDI (11), and real-time PCR
(quantitative PCR [qPCR]) is considered a reliable and rapid single test for the detection
of C. difficile toxin (12–15). The purpose of this study was to compare the performance
of the cobas Cdiff test to that of the direct and enriched toxigenic culture method for
the detection of toxigenic C. difficile in stool samples.
(The data were presented in part at annual meetings of the American Society for
Microbiology [16] and the Association for Molecular Pathology [17].)
RESULTS
Study population. A clinical utility study was performed by using 683 specimens
collected from 4 collection sites, and all specimens had valid test results with the cobas
Cdiff test as well as direct culture from initial testing. One sample lacked a sufficient
volume for repeat direct and enrichment culture methods and was not included in the
final statistical analysis. Demographics and baseline characteristics of evaluable sub-
jects are shown in Table 1. The age range of the patients was between 3 and 99 years,
with a median age of 59 years. The gender distribution was 306 males (44.8%) and 377
females (55.2%).
Comparison of the cobas Cdiff test with direct culture methods. The perfor-
mance of the cobas Cdiff test compared to that of the direct culture method is shown
in Table 2. The overall percent agreement (OPA) was 95.3%. The three specimens with
false-negative cobas Cdiff test results relative to the direct culture method were all
negative by the Xpert Cdiff test. Of the 29 specimens with false-positive cobas Cdiff test
results relative to direct culture, 15 were positive by the Xpert Cdiff test; 1 sample was
not tested because of an insufficient specimen volume.
The clinical performance of the cobas Cdiff test compared with the combined results
of initial and repeat direct and enriched toxigenic culture methods is shown in Table 3.
TABLE 1 Demographics and baseline characteristics of evaluable subjects
Characteristic
Value for evaluable
subjects (n  683)
Age (yr)
Mean  SD 56 19.4
Median 59
Range 3–99
No. (%) of subjects of sex
Male 306 (44.8)
Female 377 (55.2)
No. (%) of subjects of ethnicity
Hispanic/Latino 14 (2.0)
Not Hispanic/not Latino 646 (94.6)
Unknown 23 (3.4)
No. (%) of subjects of race
American Indian/Alaskan Native 1 (0.1)
Asian 14 (2.0)
Black/African-American 90 (13.2)
Native Hawaiian/Pacific Islander 1 (0.1)
Caucasian 549 (80.4)
Other 5 (0.7)
Unknown 23 (3.4)
No. (%) of subjects with history of prior or current antibiotics
Yes 235 (34.4)
No 448 (65.6)
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These data demonstrate the benefit of the use of enrichment culture methods to
enhance the recovery of C. difficile when cultures are used as a reference method. The
sensitivity and specificity of the cobas Cdiff test were 92.9 and 98.7%, respectively; the
positive predictive value (PPV) and negative predictive value (NPV) were 94.9 and
98.2%, respectively. In the discrepancy analysis, of the 7 specimens with false-positive
cobas Cdiff test results relative to combined direct and enrichment culture methods, 3
were positive by the Xpert Cdiff test. The 10 specimens with false-negative cobas Cdiff
test results were all negative by the Xpert C. difficile Epi test.
Impact of sample storage. The results for 124 random samples returned to the
reference laboratory for retesting had positive percent agreement, negative percent
agreement, and overall percent agreement values between fresh and frozen stool
specimens of 97.1% (33/34 samples), 97.8% (88/90), and 97.6% (121/124), respectively
(chi-square statistic, 0.02; P  0.89). For the 100 contrived specimens, the positive
percent agreement between the cobas Cdiff test results before and those after one
freeze-thaw cycle was 100.0% (100/100; 95% confidence interval [CI], 96.4 to 100.0%).
There was no difference in the distributions of positive and negative cobas Cdiff test
results when fresh and frozen specimens from the multicenter trial of 580 samples were
compared (P  1 by Fisher’s exact test; P  0.93 by the chi-square test likelihood ratio).
Finally, there was 100% agreement between direct and repeat toxigenic culture results
for 87 samples cultured fresh and following storage for at least 60 days at 20°C or
colder (Kappa statistic, 1.0).
Analytical performance. Analysis of the precision study data showed that at 1
the limit of detection (LOD), the positivity rate was 29%, and at 1 or 3 the LOD, it
was 100%. The mean cycle threshold (CT) values were 38.5 at 1 the LOD and 37.5 at
3 the LOD, with standard deviations of 1.5% and 1.1%, respectively (18).
In the analysis of clinical reproducibility, the positive percent agreement values for
results below the LOD, 1 the LOD, and 3 the LOD were 66.1% (95% CI, 58.7% to
73.0%), 100.0% (95% CI, 98.0% to 100.0%), and 100.0% (95% CI, 97.9% to 100.0%),
respectively. The negative percent agreement was 100.0% (95% CI, 97.9% to 100.0%).
TABLE 2 Comparison of the cobas Cdiff test with direct culturea
cobas Cdiff test result
No. of specimens with result
Total no. of
specimens
Positive by
direct culture
Negative by
direct culture
Positive 110 29 139
Negative 3 541 544
Total 113 570 683
aThe positive percent agreement between the results of the cobas Cdiff test and direct culture was 97.3%
(95% CI, 92.5% to 99.1%). The negative percent agreement between the results of the cobas Cdiff test and
direct culture was 94.9% (95% CI, 92.8% to 96.4%). The overall percent agreement between the results of
the cobas Cdiff test and direct culture was 95.3% (95% CI, 93.5% to 96.7%).
TABLE 3 Comparison of the cobas Cdiff test with combined direct and enrichment
cultureb
cobas Cdiff
test result
No. of speicmens with result
Total no. of
specimens
Positive by combined direct
and enrichment culture
Negative by combined direct
and enrichment culture
Positive 131 7 138
Negative 10 534 544
Total 141 541 682a
aOne sample had an insufficient sample volume for repeat testing and is not included.
bThe sensitivity and specificity of the results of the cobas Cdiff test were 92.9% (131/141 samples; 95% CI,
87.4% to 96.1%) and 98.7% (534/541 samples; 95% CI, 97.4% to 99.4%), respectively. The positive and
negative predictive values of the cobas Cdiff test were 94.9% (95% CI, 89.9% to 97.5%) and 98.2% (95% CI,
96.6% to 99.0%), respectively.
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The LOD for C. difficile strains ranged from 54 to 225 CFU per swab. The inclusivity study
found that all 28 C. difficile strains were determined to be positive in95% of replicates
at densities ranging from 77.9 to 460 CFU/swab; 15 were determined to be positive
100% of the time (18).
Analytical specificity testing found that that none of the organisms tested interfered
with the detection of the intended C. difficile targets, and there were no false-positive
results (19). The compounds listed in Table 4 were tested for interference. There was no
interference found for any material other than mucin, which interfered with the
detection of toxigenic C. difficile isolates at a 50% (vol/vol) concentration. For the
cross-contamination analysis, in the nine checkerboard runs, 1 out of 423 negative
samples produced a positive result, for a cross-contamination rate of 0.24%. None of
the 282 negative samples from the carryover contamination runs produced a positive
result (19).
Rate of invalid results. Among 683 specimens tested for toxigenic C. difficile, the
initial failure rate was 0% (0/683 specimens; 95% CI, 0% to 0.7%), and no retesting was
needed, providing a final failure (invalid) rate of 0%. Thus, there were no invalid runs
during this study.
Statistical opinion. The performance of the cobas Cdiff test was comparable to that
of toxigenic culture using unformed stool samples from subjects suspected of having
CDI and met the criteria specified in the study protocol, assay product requirements,
and clinical validation plan. The results support the intended use of the cobas Cdiff test
as an aid in the diagnosis of CDI in humans in conjunction with clinical and epidemi-
ological risk factors.
DISCUSSION
In our large, prospective, multisite clinical investigation, we demonstrated that the
cobas Cdiff test is a robust test for the detection of toxigenic C. difficile. Our results
extend those reported previously by Moure and colleagues, who found that the
TABLE 4 Compounds tested for possible interference
Substance Concn
Fecal fat 4–28 (wt/vol)
Whole blood 25, 50 (vol/vol)
Mucin 25, 50 (wt/vol)
Calcium carbonate (Tums) 10% (wt/vol)
Vancomycin 1% (wt/vol)
Metronidazole 10% (wt/vol)
Loperamide (Imodium A-D) 10% (wt/vol)
Stool softener 10% (wt/vol)
Bismuth subsalicylate (Pepto-Bismol; Procter & Gamble) 10% (vol/vol)
Nystatin ointment USP 10% (wt/vol)
Preparation H with Bio-Dyne cream (Wyeth) 10% (wt/vol)
Gynol II 10% (wt/vol)
Vagisil anti-itch cream 10% (wt/vol)
Anusol Plus 10% (wt/vol)
Sunscreen 1% (wt/vol)
Miconazole (Monistat 7) 10% (wt/vol)
Vaseline 10% (wt/vol)
SAB-dimenhydrinate suppositories (Sabex) 10% (wt/vol)
Mineral oil 10% (vol/vol)
Equate natural vegetable laxative 10% (wt/vol)
Bisacodyl (Dulcolax) 10% (wt/vol)
Fleet (CB Fleet Company) 10% (wt/vol)
K-Y Jelly/Gelée (McNeil-PPC) 1% (wt/vol)
Afrin original nasal spray 10% (vol/vol)
Witch hazel Liquid from 1 wipe/swab
E-Z-HD high-density barium sulfate for suspension
(E-Z-EM Canada)
20% (wt/vol)
Palmitic acid 10% (wt/vol)
Stearic acid 10% (wt/vol)
Naproxen (Aleve) 10% (wt/vol)
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concordance between cobas Cdiff test results and glutamate dehydrogenase (GDH)/
toxin gene screening was 97.6% (20). Also, we demonstrated the stability of sample
storage, which will be useful for future test development of next-generation molecular
and culture-based CDI diagnostics.
The genomics of C. difficile and the molecular structure of its toxin genes are well
known (6, 9, 21, 22). Thus, the design of primers and probes for a robust real-time PCR
assay is relatively straightforward. We demonstrated that the cobas Cdiff test had
excellent analytical sensitivity, inclusivity, and reproducibility prior to beginning the
clinical trial. We also demonstrated that there was minimal interference from other
substances possibly found in the stool specimens of patients. Therefore, it was not
surprising that the clinical performance of this test was robust. From the laboratory use
perspective, we also demonstrated that the new assay is reliable in that the initial
failure rate of the test was 0% (0 of 683 tests), which facilitates deployment in a
diagnostic microbiology laboratory for clinical use.
For our literature review, we used PubMed.gov (MEDLINE) with the search terms
Clostridium difficile diagnosis, Clostridium difficile genetics, and real-time PCR and
the names of U.S. Food and Drug Administration (FDA)-cleared molecular tests that
detect C. difficile to search the medical literature from 2005 through June 2017. We
also searched Google using these terms as well as the FDA website (https://www
.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/
ucm330711.htm) to determine which commercial tests were available as CDI assays.
From this review, it is clear that there are potentially three main issues to consider when
selecting a testing program for facilitating the diagnosis of CDI. One issue is how well
the various molecular tests perform. The second issue is what the best testing approach
is. The third issue, as an emerging approach to CDI control, is how the chosen test
might perform in an admission active surveillance testing (AST) program to prevent the
spread of C. difficile in acute-care hospitals.
The reported performances of the available molecular tests for the detection of
toxigenic C. difficile were recently reviewed (11). Of the 11 tests reviewed, the assays
that consistently showed 90% sensitivity and specificity were limited to the Cepheid
Xpert C. difficile, Portrait Toxigenic C. difficile, and Illumigene C. difficile assays (22). In our
large, multicenter trial, the cobas Cdiff test performed at least as well as the other
assays when our results were compared to those results.
The question of which test or series of tests (e.g., algorithm) should a clinical
laboratory implement is critical for this disease and very complex for the laboratory. A
key argument has been that molecular qPCR tests are too sensitive and detect not only
disease but also colonization. However, there is no evidence that disease is related to
the level of toxin detected in stool (23). One of the frequently referenced clinical reports
on this topic is that by Polage and colleagues, who concluded that PCR tests were too
sensitive and detected an excess of colonized patients as well as those with disease
(24). Unfortunately, those researchers did not use any clinical criteria or laboratory
assessment of specimen quality to determine who should actually be evaluated (e.g.,
included in their data assessment were patients with 3 diarrheal stools per day who
were not excluded from potential CDI cases) in the data that were critically analyzed
(24). Thus, it is not surprising that those researchers found a high number of positive
specimens from patients with no significant diarrhea, given that it is not unusual for
hospitalized patients to be colonized with this organism (25). Our own data suggest
that PCR-positive, direct stool toxin-negative patients have a significant risk for future
complications if not treated (26). We found a significant positive effect of receiving
treatment on reducing 90-day readmission for any reason, decreasing the inpatient
length of stay (LOS) and total LOS (inpatient plus readmission LOS), and reduced
charges in the enzyme-immunoassay-negative (EIA)/PCR	 group versus the EIA	/
PCR	 group, suggesting that at least some of these patients actually had clinically
significant CDI. Importantly, a recent clinical effectiveness review (CER) from the Agency
for Healthcare Research and Quality (AHRQ) found that nucleic acid amplification tests
(NAATs) had high sensitivity and specificity for the laboratory detection of CDI with the
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highest-quality evidence (27). The lowest-quality evidence was the use of algorithms
for this endeavor, and while the algorithms were specific, this approach lacked
sensitivity (27). Clinical diagnosis is essential for the diagnosis of CDI (25), as is well
stated in another recent review: “The diagnosis of CDI is primarily based on the
clinical signs and symptoms and is only confirmed by laboratory testing” (11). Thus,
in the appropriate clinical setting, the use of the most sensitive assay for the
detection of toxigenic C. difficile in a patient’s stool sample should remain the goal
of the laboratory.
A novel question being asked of these tests is whether NAATs can be useful for the
control of CDI in the acute-care setting by using them as screening tests (AST) at the
time of admission for the detection of C. difficile carriers, who can then be subjected to
contact precautions to prevent spread to other patients (10). A recent report illumi-
nating the better understanding of CDI epidemiology indicates that asymptomatic
carriers (e.g., colonized persons) are important sources of ongoing hospital transmis-
sion (28). Another investigation comparing the likely transmission of C. difficile from
patients whose stool samples were positive by direct toxin testing as well as positive
(by qPCR) for a toxin gene versus those that were positive only for the toxin gene found
that symptomatic patients with qPCR-positive toxigenic C. difficile infection (without
fecal toxin being detected) accounted for at least one-quarter of potential hospital
transmission events (29). A third important study demonstrated that at the time of
admission, patients acquire new organisms from their surrounding environment but
that after the first night, they contribute bacteria (e.g., contaminate the room environ-
ment) until the microbiological representation of the patient and the room becomes
quite homogeneous (30). This implies that if one is contemplating AST for pathogens
that can spread within the hospital, a rapid (24-h), sensitive test such as qPCR is
needed. There has been one report that showed success in the use of the AST
approach, where the investigators found an overall reduction in the number of patients
who developed hospital-associated CDI from 416 patients (6.9 per 10,000 patient-days)
during the control period to 38 patients (3.0 per 10,000 patient-days; 56.5% reduction)
during the admission testing period (P  0.001), suggesting that AST for toxigenic C.
difficile is useful (31).
Our research had limitations in that there is no “perfect gold standard” for compar-
ison with any new test developed to diagnose Clostridium difficile infection, but rather,
they target toxigenic C. difficile. We used toxigenic culture as an accepted reference
method for detecting toxigenic C. difficile (32), combined with broth enrichment to
enhance sensitivity (14). We also demonstrated a potential cross-contamination rate of
0.24% (1 of 423 negative samples) when using high-signal-positive samples, demon-
strating that cross-contamination is possible but that the risk is low. Thus, we believe
that the clinical trial data are valid as a result of all the comparisons performed and that
this study demonstrates the reliability of the cobas Cdiff test as a new automated test
for the laboratory confirmation of CDI.
Future research will be useful in developing laboratory diagnostics that are able to
separate colonization from disease attributed to C. difficile. This will be a challenge,
since at this time, there is no acceptable, clear standard for definitively classifying who
does and who does not have CDI. Also, defining the role of rapid molecular diagnostics
in the prevention and control of health-care-onset CDI should be a priority, as this
disease remains an increasing threat in our current environment. The best practice(s) to
minimize this threat remains uncertain (10). Third, validation of assay performance
using perirectal admission swabs for active surveillance testing to detect colonization
is needed for this and other tests targeting toxigenic C. difficile.
In conclusion, we have demonstrated that the cobas Cdiff test is a reliable and
robust automated assay for the detection of toxigenic C. difficile in stool samples from
patients with diarrhea. It has entered the commercial testing market with other
laboratory tests for confirming the diagnosis of CDI as a useful clinical diagnostic tool.
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MATERIALS AND METHODS
Study population. Stool samples were collected from 683 eligible patients over a 5-month period
at 4 sites in the United States (NorthShore University HealthSystem, Evanston, IL; hospitals using TriCore
Reference Laboratories located in Albuquerque, NM; Indiana University School of Medicine, Indianapolis,
IN; and Thomas Jefferson University, Philadelphia, PA). Patients 12 months of age who were being
tested for the diagnosis of CDI were identified and enrolled in the study. Each patient entering the study
had an unformed stool sample of 5 ml submitted for testing. Patients were excluded from the study
if they (i) submitted a formed stool sample, (ii) had been administered antibiotic therapy against C.
difficile (e.g., oral and/or parenteral metronidazole, oral vancomycin, or fidaxomicin) during their present
hospitalization, (iii) were previously enrolled in this study, (iv) were enrolled in any other study focused
on the prevention or treatment of CDI within the previous 12 months, or (v) had a contraindication for
the collection of stool samples according to institution policies and procedures.
Clinical trial design. The clinical performance of the cobas Cdiff test was evaluated in a prospective,
multisite investigation comparing the results of this test with those of toxigenic culture methods using
remnant, deidentified, unformed stool samples from eligible subjects. Toxigenic culture was performed
at a single site designated the reference laboratory (NorthShore University HealthSystem). The cobas
Cdiff test was performed at the other three sites, according to the manufacturer’s instructions.
This study was conducted in compliance with International Conference on Harmonization (ICH)
guidelines, good clinical practice (GCP) guidelines, and regulations of the FDA. Approval by the
institutional review boards at all four sites was obtained. This study was performed to obtain clearance
of the cobas Cdiff test by the FDA.
Stool sample processing. On the day of sample collection, fresh stool specimens were transported
to the collection site laboratory at temperatures of between 2°C and 30°C. Upon receipt, fresh stool
samples were processed within 48 h of collection. The accepted liquid and unformed samples of fresh
stool were stirred to homogenize them, and aliquots were then prepared by transferring 1.0-ml
portions into 4 separate, sterile, 5-ml cryogenic vials, as depicted in Fig. 1. Aliquots 1 and 2 were shipped
on cold packs to one of the designated test sites for C. difficile PCR testing within 5 days of sample
collection. Aliquots 3 and 4 were shipped on ice to the reference laboratory to arrive within the same
time frame.
Toxigenic culture. The toxigenic culture included initial and repeat direct and enrichment cultures
of stool specimens followed by cytotoxicity testing. Direct culture was done by inoculating a portion of
the sample into prereduced anaerobically sterilized (PRAS) selective medium and cycloserine-cefoxitin-
fructose agar with horse blood and taurocholate (CCFA-HT; Anaerobe Systems, Morgan Hill, CA), followed
by cytotoxicity testing on recovered C. difficile bacteria. Briefly, after incubation at 35°C, suspected
colonies were identified as being C. difficile by Gram staining, aerotolerance testing, and testing using the
Pro Disk test (Hardy Diagnostics, Santa Maria, CA) and then inoculated into anaerobic chopped-meat
broth (Anaerobe Systems), which was incubated for 5 to 7 days at 35°C for cytotoxicity testing. The
supernatant from the anaerobic chopped-meat broth was processed for the detection of C. difficile toxin
B by cell culture cytotoxicity testing according to the manufacturer’s instructions (C. Difficile Tox-B test;
Techlab, Blacksburg, VA). An enriched toxigenic culture method was performed simultaneously using
anaerobic cycloserine-cefoxitin-mannitol broth with taurocholate, lysozyme, and cysteine (CCMB-TAL;
Anaerobe Systems), followed by subculturing on anaerobic Brucella agar plates (Anaerobe Systems), with
identification and cytotoxicity testing of all recovered C. difficile isolates.
A specimen was considered positive for toxigenic C. difficile if a toxin-producing organism was
recovered from a stool specimen in a direct or enriched toxigenic culture (any positive rule). If C. difficile
was isolated from the direct culture and the isolate tested positive by a cell cytotoxicity assay, the
enrichment culture was not further analyzed. By using aliquot 4 specimens that were frozen at70°C for
up to 5 months, 580 study samples were retested by direct and enriched culture methods. If a stool
specimen was positive by the cobas Cdiff test but negative by the initial culture, a repeat culture was
done (n  29). Also, all other samples with a negative initial direct culture result (n  541) had a repeat
direct and enriched culture performed. Additionally, 10 specimens with a positive initial direct culture
result were tested as positive controls. Specimens were classified as being negative for toxigenic C.
difficile only if they tested negative by both initial as well repeat direct and enrichment culture methods.
Testing of patient samples on the cobas 4800 system. After receipt of patient specimens in the
laboratory, test orders were logged into the cobas 4800 system either manually, with a work list, or via
a Laboratory Information System (LIS) interface and then tested. The cobas 4800 system is a walk-away
platform to perform nucleic acid purification and real-time PCR (qPCR) set up in a 96-well plate, followed
by manual sealing and transferring of the plate to the amplification and detection system (33). The
system currently is available for methicillin-resistant Staphylococcus aureus (MRSA)-S. aureus (34), C.
difficile (this study), herpes simplex virus 1 (HSV-1) and HSV-2 (35, 36), Chlamydia trachomatis-Neisseria
gonorrhoeae (37–42), and high-risk human papillomavirus (43–45) testing and BRAF (46), epidermal
growth factor receptor (EGFR) (47), and KRAS (48) mutation detection. The cobas MRSA/SA test, the cobas
Cdiff test, and the cobas HSV 1 and 2 test can be performed simultaneously in a single testing run. This
system uses the cobas x 480 instrument, which includes an automated pipetter to extract, purify, and
prepare target nucleic acid for qPCR (e.g., automated specimen preparation). Bacterial lysis of the stool
specimen is achieved with proteinase K, detergent, and a chaotropic agent. The purified DNA is bound
to magnetic glass particles (MGPs), washed, and eluted. The cobas x 480 instrument next transfers the
working master mix reagent and moves the specimen to the qPCR microwell plate. The plate is then
transferred to the cobas z 480 instrument where the amplification and detection of target DNA and
controls occur by using specific primers and probes. Data analysis and report generation are performed
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with cobas 4800 software. The cobas Cdiff test uses positive and negative controls (cobas 4800 Cdiff
Controls and Cofactor kit) and an internal control (cobas 4800 system internal control kit). One set of
positive and negative controls is included in each run. Valid results must be obtained for both the
positive and negative controls for the cobas 4800 software to display a reportable result.
Discrepancy analysis. Discrepancy analysis using the Xpert C. difficile/Epi test (Cepheid, Sunnyvale,
CA) was performed on all samples with discordant results between the cobas Cdiff test and the combined
direct and enrichment culture method. Eight concordant positive and eight concordant negative
samples were also tested as controls. The results of the Xpert C. difficile/Epi test determined the final
reference result for the discrepancy analysis.
Testing of fresh and archived (frozen) stool specimens. To evaluate the effect of specimen storage
on the results of toxigenic culture and the cobas Cdiff test, aliquots from contrived specimens and
unformed stool samples prospectively collected from patients suspected of having CDI were tested fresh
and following storage at 20°C or colder. Briefly, four studies were performed; specifically, (i) toxigenic
culture was performed on fresh samples at the reference laboratory before the samples were shipped
frozen on dry ice to Roche Molecular Systems, Inc. (Pleasanton, CA), for PCR, and following PCR, a subset
was returned for a repeat culture; (ii) a panel of 100 contrived specimens was prepared by using fresh
negative stool specimens spiked with toxigenic C. difficile at various densities (2.5-, 5.0-, 10-, and
20-fold-higher densities than the assay limit of detection) and tested fresh plus following storage for 32
days at 20°C  5°C; (iii) the assay also was run on the 580 prospectively collected samples, both fresh
and following storage at 70°C for up to 5 months; and (iv) a repeat toxigenic culture was performed
on a subset of clinical samples (15 culture-positive and 72 culture-negative samples) stored at 20°C or
colder for 60 days.
FIG 1 Processing of unformed stool specimens from subjects with suspected Clostridium difficile infection.
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Analytical performance. The technical performance verification (TPV) study was conducted by using
a panel composed of C. difficile cultures diluted into a negative stool matrix in cobas PCR medium to a
density below the LOD, near the LOD, and above the LOD as well as a negative level composed of only
the stool suspension in cobas PCR medium. We used three unique lots of cobas Cdiff test reagents and
three instruments for a total of 36 runs over 12 days.
The reproducibility of the results of the cobas 4800 system was established by a multisite investi-
gation using simulated clinical samples evaluated across lot, site/instrument, operator, and day and
within a run. Reproducibility test panels consisted of four specimens, with three replicates each, using
various densities of C. difficile strain ATCC 43255 (negative, below the LOD, 1 the LOD, and 3 the LOD)
in a pooled, C. difficile-negative, unformed stool matrix in cobas PCR medium. These specimens were
tested at three sites by two operators/day (six operators total) for 5 days per lot over two lots for an
overall total of 712 valid tests. We modeled the target CT value as the dependent variable using the
random effects lot, site, operator, and day.
The LOD was determined by analyzing quantified cultures of seven toxigenic C. difficile strains diluted
into a pooled negative stool specimen matrix in cobas PCR medium. All densities were analyzed by using
three unique reagent lots. At least 21 replicates per reagent lot were tested at each density. To assess
inclusivity, the cobas Cdiff test was evaluated with 28 additional strains of toxigenic C. difficile tested at
a minimum of three densities and with 40 replicates per density level. The lowest density that had a
95% hit (positive-detection) rate was considered the LOD for each strain.
Analytical specificity was evaluated with a panel that consisted of 103 bacteria, fungi, and viruses as
well as one human tissue cell line (18). In addition, 28 Clostridium genus organisms, including nontoxi-
genic C. difficile, were tested (18). Bacteria were quantified as CFU per milliliter, human cells were
quantified as cells per milliliter, and viruses were quantified as PFU per milliliter. The only exceptions
were for the following microorganisms: Chlamydia trachomatis was quantified as elementary bodies (EB)
per milliliter, and cytomegalovirus, human echovirus, and human enterovirus were quantified as IU per
milliliter. Bacteria and human cells were spiked to 1 106 CFU/ml and 1 106 cells/ml, respectively, and
all viruses were spiked to 1  105 PFU/ml, except for adenovirus type 40, cytomegalovirus (human
herpesvirus 5 [HHV5]), and human rotavirus, which were spiked to lower densities due to stock density
limitations. Testing was performed with the organisms alone or with two C. difficile isolates present
individually at 3 the LOD.
Interference was evaluated for 26 medications, fecal fat, whole blood, and mucin. The effects of the
potentially interfering substances were evaluated in the presence and absence of two toxigenic C. difficile
isolates spiked to 3 the LOD of the cobas Cdiff test (54 CFU/ml and 113 CFU/ml for the two strains).
Potential cross-contamination was assessed by testing a series of high-positive toxigenic C. difficile
samples and negative samples in a checkerboard configuration on the cobas 4800 system. High-positive
samples were prepared by spiking a pooled negative stool matrix sufficient to generate a CT value (i.e.,
the number of PCR cycles until the PCR growth curve was classified as positive) of the 95th percentile of
the clinical specimen population. A total of 94 samples were included per run, with nine runs being
performed, using three cobas 4800 systems with alternating checkerboard configurations. A total of
three runs of negative samples following these checkerboard runs were performed to assess carryover
contamination.
Statistical analysis. SAS/STAT software (SAS, Cary, NC) was used to perform all analyses. Statistical
analyses of clinical samples were chosen based on statistical guidance from the FDA (49, 50) and in
accordance with the guidelines of Clinical and Laboratory Standards Institute method EP12-A2 for
evaluating qualitative test performance (19). For the clinical reproducibility study, 95% two-sided exact
binomial confidence intervals were used. In the studies designed to examine the difference between
results from fresh and those from frozen samples, statistical analysis was done by using two-sided Fisher’s
exact test and the likelihood ratio of the chi-square test.
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